Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Proteasomal dysfunction in sporadic Parkinson's disease.

Kevin St P McNaught1, Tehone Jackson, Ruth JnoBaptiste

  • 1Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA. kevin.mcnaught@mssm.edu

Neurology
|May 24, 2006
PubMed
Summary

Proteasomal dysfunction may cause neuron death in Parkinson's disease (PD). Further research is needed to determine if this is a primary or secondary factor in PD progression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A double-blind, controlled trial of circadian effective light therapy in patients with Parkinson's disease.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2025
Same author

CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trial.

EClinicalMedicine·2024
Same author

Continuous Levodopa Delivery with an Intraoral Micropump System: An Open-Label Pharmacokinetics and Clinical Study.

Movement disorders : official journal of the Movement Disorder Society·2024
Same author

Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial.

The Lancet. Neurology·2024
Same author

A Phase I, Randomized, SAD, MAD, and PK Study of Risvodetinib in Older Adults and Parkinson's Disease.

Journal of Parkinson's disease·2024
Same author

Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial.

The Lancet. Neurology·2023

Area of Science:

  • Neuroscience
  • Biochemistry

Background:

  • Neuronal death in sporadic Parkinson's disease (PD) remains poorly understood.
  • Recent findings indicate alterations in proteasomal function in PD brains.

Purpose of the Study:

  • To investigate the biochemical basis of proteasomal dysfunction in PD.
  • To determine the relevance of proteasomal dysfunction to PD pathogenesis.

Main Methods:

  • Biochemical analysis of proteasomal function in patient brain samples.
  • Investigating potential causes of proteasomal dysfunction.

Main Results:

  • Proteasomal dysfunction is suggested to underlie protein accumulation, Lewy body formation, and neurodegeneration in PD.
  • Potential causes include gene mutations, oxidative damage, ATP depletion, or environmental toxins.

Related Experiment Videos

Conclusions:

  • Proteasomal dysfunction is a potential contributor to PD.
  • The precise role (primary or secondary) of proteasomal dysfunction in PD initiation and progression requires further investigation.